Moisturizing Eyes, Soothing Hearts, Enhancing Vision—A Report on the Launch Event for Nanjing Runyou’s New Ophthalmic Equipment

Release Date:

2026-05-25

A dazzling night, ushering in a new chapter! On May 21, during the Tianjin East–West Conference, Nanjing Runyou Fa’ong held a successful launch event for its new UVC and UVA pet ophthalmology products. Leading pet ophthalmology experts, industry partners, and all colleagues from Runyou gathered to witness this groundbreaking moment in veterinary eye care.

Opening Remarks

Runyou UVC/UVA: Advancing the Standardization of Veterinary Ophthalmology Technology

Mr. Zhao Qiang, General Manager of Nanjing Runyou, delivered an enthusiastic opening address. He noted that, with the rapid growth of China’s pet‑healthcare sector, demand for ophthalmic care is steadily increasing. However, conditions such as corneal infections and ulcers have long been plagued by challenges including high drug resistance, prolonged treatment courses, elevated surgical risks, and low owner acceptance. Upholding the philosophy of “putting pets first, accelerating recovery,” Runyou has focused on the R&D of precision ophthalmic instruments for pets. The launch of its two innovative devices, the FaWeng UVC and UVA, is aimed at addressing these clinical hurdles and providing veterinarians with more efficient, safer diagnostic and therapeutic solutions. Looking ahead, Runyou will continue to place technological innovation at the heart of its mission, working to standardize and popularize ultraviolet‑based ophthalmic technologies, collaborating with industry partners to elevate treatment standards, and leveraging Chinese manufacturing to safeguard the clear vision of countless furry companions.

Dr. Lai Xiaoyun’s Address

Recognized Runyou’s new product as a “paradigm of the integration of clinical practice and technology.”

Several leading industry experts took the stage one after another to lend their support and voice to this new product launch. In his address, Dr. Lai Xiaoyun—Secretary-General of the East–West Small Animal Clinical Veterinarians Conference and founder of the East–West Veterinary Platform—offered high praise for the launch from a macro perspective on industry development. He noted that veterinary ophthalmology is among the fastest‑growing and most urgently needed specialties in China, yet corneal diseases, as a common clinical concern, have long lacked effective, non‑invasive solutions. The FaWang UVC and UVA devices, leveraging innovative ultraviolet technology, directly address these clinical challenges, overcoming the limitations of conventional drug‑based and surgical treatments and providing clinicians with a cutting‑edge, practical new tool. Dr. Lai emphasized that progress in the field hinges on the deep integration of clinical practice and technological innovation, and that Runyou’s latest offerings exemplify this synergy. Not only will they deliver safer, more comfortable care for affected pets, but they will also help elevate the overall standard of veterinary ophthalmic diagnosis and treatment. He expressed his anticipation of partnering with Runyou to jointly advance the adoption and enhancement of industry‑wide diagnostic and therapeutic standards.

Speech by Dean Wang Jie

Highly commends FaFeng® UVC/UVA for overcoming drug resistance and eliminating the need for anesthesia, bringing bright hope.

Dr. Wang Jie, who has spent more than a decade at the forefront of veterinary ophthalmology—serving as the director of Shenzhen Ruipai Paiteburg Pet Hospital and vice-chair of the United Chinese Veterinary Ophthalmology Committee (UCVO)—shared, drawing on his clinical experience with over 2,000 corneal disease surgeries, the real‑world pain points and challenges in treating infectious and pathological conditions of the pet cornea. He noted that in practice, issues such as multidrug‑resistant bacterial infections, corneal melting, and ulcer perforation have long posed formidable challenges for veterinarians. Traditional treatment regimens are not only lengthy and of limited efficacy but are often hindered by factors like anesthesia risks and owner concerns. Dr. Wang highly commended the technological breakthroughs of FaWang’s UVC and UVA devices: FaWang’s deep‑ultraviolet photodynamic disinfection technology can rapidly inactivate a broad spectrum of pathogenic microorganisms, including multidrug‑resistant strains, within just five seconds—without relying on antibiotics—offering a non‑invasive, highly effective first‑line treatment for infectious keratitis. Meanwhile, FaWang’s world‑first UVA corneal crosslinking system, which requires no anesthesia, employs photochemical crosslinking to strengthen the corneal collagen matrix, effectively halting corneal melting while significantly lowering both the procedural threshold and anesthesia risks, thereby enabling more affected pets to receive timely care. He emphasized that the integrated therapeutic loop created by these two devices—“rapid infection control plus robust corneal stabilization”—will fundamentally transform the landscape of pet corneal disease management, equipping clinicians with more powerful diagnostic and therapeutic tools and offering hope for restored vision to an increasing number of afflicted animals.

Address by Dean Gao Hui

Fafeng® UVC/UVA Sets a New Standard in Ophthalmology

This press conference featured a special guest: Dr. Gao Hui, a leading domestic expert in veterinary ophthalmology and the director of Shanghai Felis Veterinary Ophthalmology Hospital, as well as the chair of the United Council for Veterinary Ophthalmology (UCVO). Dr. Gao shared clinical cases, highlighting that ultraviolet light technology offers veterinarians a critical therapeutic option “beyond medication and before surgery.” UVC, with its exceptionally strong surface‑level bactericidal power, rapidly controls infection and reduces the risk of perforation, while UVA cross‑linking fundamentally strengthens corneal biomechanical integrity, halting dissolution and stabilizing lesions. Together, these two modalities create a comprehensive closed loop—“rapid infection control plus robust structural stabilization”—delivering remarkable results in complex, severe corneal cases and significantly improving both eye‑preservation rates and healing outcomes. Dr. Gao highly commended the safety, convenience, and clinical utility of FaWang’s UVC and UVA technologies, asserting that they will become standard protocols in veterinary ophthalmology, ushering domestic diagnosis and treatment of corneal diseases into a new era of greater efficiency, enhanced safety, and broader accessibility.

Features and Advantages of Fafon® UVC and UVA

At the launch event, Mr. Cai Shang, Head of the Marketing Department at Nanjing Runyou, provided a detailed overview of the outstanding technical features of the FaWang UVC and UVA ophthalmic devices.

Fafeng® UVC Corneal Infection Treatment Device: Non-invasive physical disinfection, saying goodbye to drug resistance. predicament

Key Features and Advantages:

· Precision deep‑UV disinfection: Utilizing 265 nm deep‑UV light, it precisely targets pathogenic microbial DNA, physically inactivating bacteria, fungi, and multidrug‑resistant strains—without reliance on chemical agents—thereby addressing the root cause of resistance.

· Second‑level non‑invasive treatment: A single session is completed in just 5 seconds, with contactless, non‑invasive delivery that targets only the corneal surface without damaging healthy corneal tissue. Host cells can rapidly repair the treated area, significantly reducing treatment risks.

· Broad-spectrum, highly effective across all clinical scenarios: It exhibits potent antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and more. Without waiting for susceptibility test results, it can be promptly used in emergency settings, for mixed infections, and in routine anti-infective therapy, thereby gaining valuable time for clinical management.

· Safe, convenient, and easy to use: The procedure is straightforward, requires no special consumables, and can be performed without anesthesia, ensuring high patient acceptance. It can be completed quickly in the outpatient setting, significantly improving diagnostic and treatment efficiency.

Fauon® UVA Corneal Cross-Linking Device: A world-first, no anesthesia required, strengthening the cornea to safeguard sight.

Key Features and Advantages

· Non‑invasive crosslinking for robust corneal stabilization: Utilizing 370 nm UVA light combined with riboflavin–photodynamic crosslinking, this technique reconstructs the corneal collagen fiber architecture, markedly enhancing corneal mechanical strength and effectively preventing corneal dissolution and ulcer progression, with a clinical cure rate as high as 97%.

· World’s first anesthesia-free treatment: No general anesthesia is required—only topical anesthesia is needed to complete the procedure, completely eliminating anesthesia-related risks and significantly lowering the clinical threshold, enabling more pets to receive timely care, particularly those that are high-risk, elderly, or frail and ill.

· Precise safety, efficient and convenient: Equipped with precise focusing, an adjustable aperture, and an eye‑tracking–based automatic pause feature, it delivers stable, controllable energy output. Treatment can be completed in as little as 2 minutes, with multi‑level power settings to accommodate various corneal conditions, ensuring a safe and well‑controlled procedure.

· Multifaceted therapeutic benefits: Combining bactericidal, anti-inflammatory, and corneal‑repair‑promoting effects, it is indicated not only for dissolving corneal ulcers and infectious keratitis but also for a range of corneal conditions, including bullous keratopathy and corneal dystrophies, offering clinicians a one‑stop solution.

Addressing critical industry challenges such as corneal infections and corneal disorders, FaWang’s two new products—UVC and UVA—employ an innovative approach of “physical infection control plus non‑invasive corneal reinforcement” to create a comprehensive closed-loop treatment system for corneal diseases. FaWang UVC leverages deep‑ultraviolet light technology to deliver rapid, non‑invasive disinfection, reducing reliance on pharmacological treatments; meanwhile, FaWang UVA utilizes a non‑anesthetic crosslinking technique to robustly strengthen the cornea, ensuring high cure rates and safeguarding pets’ vision.

Limited-time offer is here!

By May 31, 2026, a prepayment deposit of RMB 10,000 per ophthalmic device will entitle you to the exclusive pre-sale price: the UVA animal corneal cross‑linking system at RMB 30,000 per unit (original price RMB 33,800), and the UVC animal corneal infection treatment device at RMB 34,000 per unit (original price RMB 38,800). If you purchase the UVA + UVC combination in a single transaction, you will also receive one complimentary spot in the “Advanced Specialty Course on Small Animal Corneal Disease Treatment (Hands‑On)” hosted by UCVO, valued at approximately RMB 6,000.

Conclusion
Moisturizing for the eyes, soothing for the heart, and enhancing color! In the future, Nanjing Runyou will continue to deepen its expertise in veterinary ophthalmology, leveraging cutting-edge ultraviolet technology as its driving force to push the boundaries of innovation. Working hand in hand with industry partners, we will elevate diagnostic and treatment standards, using the light of science and technology to safeguard the clear vision of countless furry companions!